Treatment Decisions for Resectable Non–Small-Cell Lung Cancer: Balancing Less With More?

Author:

O'Reilly David12ORCID,Botticella Angela3,Barry Simon1,Cotter Seamus4,Donington Jessica S.5,Le Pechoux Cecile3,Naidoo Jarushka16ORCID

Affiliation:

1. Beaumont RCSI Cancer Centre, Beaumont Hospital, Dublin, Ireland

2. RCSI StAR MD Programme, Bon Secours Hospital, Glasnevin, Dublin, Ireland

3. Department of Radiation Oncology, Gustave Roussy Cancer Campus University Hospital, Villejuif, France

4. Cancer Trials Ireland, Ardilaun Court, St Stephen's Green, Dublin, Ireland

5. Department of Surgery, Section of Thoracic Surgery, University of Chicago Medicine & Biologic Sciences, Chicago, IL

6. RCSI University of Health Sciences, Dublin, Ireland

Abstract

For patients with non–small-cell lung cancer (NSCLC), the outcomes for patients with resectable disease are historically poor compared with other solid organ malignancies. In recent years, there have been significant advances in multidisciplinary care, which have resulted in improved outcomes. Innovations in surgical oncology include the use of limited resection and minimally invasive techniques. Recent data in radiation oncology have suggested refinements in pre- and postoperative radiation therapy, resulting in optimization of techniques in the curative setting. Finally, the success of immune checkpoint inhibitors and targeted therapies in the advanced setting has paved the way for inclusion in the adjuvant and neoadjuvant settings, resulting in recent regulatory approvals for four regimens (CheckMate-816, IMpower010, PEARLS, ADAURA). In this review, we will provide an overview of the seminal studies informing advancements in optimal surgical resection, radiation treatment, and systemic therapy for resectable NSCLC. We will summarize the key data on survival outcomes, biomarker analyses, and future directions for perioperative studies.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

General Medicine

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Neo-/adjuvant immunotherapy and targeted therapy of non-small cell lung cancer;Onkologie;2023-10-05

2. A brief history of lung cancer in Canada: Care, contributions and challenges;Canadian Journal of Respiratory, Critical Care, and Sleep Medicine;2023-09-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3